11 active not recruiting, 11 completed, 8 terminated, 5 recruiting. 21 Phase 2, 17 Phase 1, 1 Not applicable, 1 Phase 3.
Follow EKG: new trials by email Literature Review of EKG trials Research Report on EKG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride - Malignant Digestive System Neoplasm | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 60 | 2026-04-30 | 2026-06-02 |
| WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring) Electrocardiogram, Echocardiogram, LVEF echocardiogram - Lymphoma, Sarcoma | Not applicable | Recruiting | Mayo Clinic | 250 | 2025-07-18 | 2025-10-15 |
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Sacituzumab Govitecan, EKG, Brain MRI - Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2025-06-09 | 2026-01-21 |
| Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Onvansertib, Gemcitabine, Nab-paclitaxel - Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2024-08-01 | 2024-07-19 | |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency Mycophenolate Mofetil, Tacrolimus, Post-Transplant Cyclophosphamide - GATA2, Immunodeficiency | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2023-11-29 | 2026-08-11 |
| Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer PRGN-2009, Pembrolizumab, EKG - Oropharyngeal Squamous Cell Carcinoma (SCC) | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 26 | 2023-11-07 | 2026-06-23 |
| Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis Pre-operative abemaciclib, Device for Cerebral Fluid Dialysate Collection, Ashion Analytics GEM ExTra - Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2023-04-07 | 2026-10-06 |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2022-06-21 | 2025-08-08 |
| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes Dilanubicel, Cyclophosphamide, Fludarabine - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 31 | 2022-05-10 | 2026-07-10 |
| Metabolic and Infectious Diseases in La Réunion (the REUNION Population-based Study) Blood, DNA, feces, urine, hair and skin microbiota collection - Infectious Disease, Cardiovascular Diseases | Recruiting | Institut National de la Santé Et de la Recherche Médicale, France | 2000 | 2022-05-01 | 2026-07-10 | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System Obinutuzumab, Prednisone, Lenalidomide - Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2022-04-19 | 2026-01-08 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Rituximab, Etoposide, Copanlisib - Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2022-03-24 | 2024-07-09 |
| T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR - Kita-kyushu Lung Cancer Antigen 1, Human | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2022-03-08 | 2025-12-02 |
| Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors Olaparib, Durvalumab, EKG - EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine | Phase 2 | Terminated | National Cancer Institute (NCI) | 4 | 2021-07-07 | 2026-09-22 |
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 348 | 2021-01-25 | 2026-08-28 |
| Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 32 | 2021-01-14 | 2026-07-14 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
| Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance CMR examination - Breast Cancer, Chemotherapy Induced Systolic Dysfunction | Unknown | RenJi Hospital | 300 | 2020-10-30 | 2023-06-01 |
Showing 20 of 37. Sign in to see all of them.
Brain Neoplasms (2) · Gastrointestinal Neoplasms (2) · Hematologic Neoplasms (2) · Leukemia, Biphenotypic, Acute (2) · Lymphoma (2) · Pancreatic Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Rectal Neoplasms (2) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Anemia, Refractory, with Excess of Blasts (1) · Anus Neoplasms (1) · Autoimmune Diseases (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1)
National Cancer Institute (NCI) (25) · Mayo Clinic (2) · OHSU Knight Cancer Institute (2) · Children's Oncology Group (1) · CorVita Science Foundation (1) · Creighton University (1) · Fred Hutchinson Cancer Center (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · RenJi Hospital (1) · Senthil G. Krishna (1) · Yael P Mosse (1)
United States (35) · Canada (1) · China (1) · France (1) · Israel (1) · Puerto Rico (1)
Charalampos Floudas, M.D. (3) · Joerg Herrmann, MD (2) · Scott M Norberg, D.O. (2) · Anish Thomas, M.D. (1) · Charles D Lopez (1) · Christopher J Melani, M.D. (1) · Danielle E Pregent-Arnold, M.D. (1) · Dimana Dimitrova, M.D. (1) · Elie Traer, MD PhD (1) · Filippo Milano (1) · James C Yang, M.D. (1) · James Gulley, M.D. (1) · James L Gulley, M.D. (1) · Jeremy L Davis, M.D. (1) · Jibran Ahmed, M.D. (1)
PMID 30227893, PMID 32109194, PMID 32508818, PMID 33558725, PMID 33602696, PMID 34607348, PMID 36844736, PMID 37682953, PMID 37882668, PMID 39500789, PMID 40116923, PMID 40721826, PMID 41180818, PMID 41671463, PMID 41779512, PMID 42307670, PMID 42498485, PMID 42605066, PMID 42820295
2015 (1), P30CA015704 (1), P30CA051008 (1), P50HL110787 (1), U10CA180820 (1), U10CA180886 (1)